Stockscreener 앱 받기
19.36
0.10%
0.02
시장 영업 전:
19.52
0.16
+0.83%
전일 마감가:
$19.34
열려 있는:
$20.31
하루 거래량:
2.55M
Relative Volume:
2.23
시가총액:
$1.24B
수익:
$193.35M
순이익/손실:
$-177.58M
주가수익비율:
-7.902
EPS:
-2.45
순현금흐름:
$-172.43M
1주 성능:
-4.77%
1개월 성능:
-6.16%
6개월 성능:
-24.58%
1년 성능:
+7.26%
1일 변동 폭
$18.48
$20.31
1주일 범위
$18.48
$20.31
52주 변동 폭
$16.60
$28.47
슈뢰딩거 Stock (SDGR) Company Profile
명칭
Schrodinger Inc
전화
503-299-1150
주소
1540 BROADWAY, NEW YORK, NY
SDGR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
19.36 | 1.42B | 193.35M | -177.58M | -172.43M | -2.45 |
|
VEEV
Veeva Systems Inc
|
279.76 | 46.19B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
58.74 | 9.61B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
58.55 | 10.89B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
91.84 | 7.86B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
33.91 | 5.92B | 906.14M | -52.62M | 89.62M | -0.3621 |
슈뢰딩거 Stock (SDGR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-07-02 | 개시 | Leerink Partners | Outperform |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Overweight |
| 2023-05-05 | 재개 | Piper Sandler | Overweight |
| 2022-12-19 | 개시 | Goldman | Neutral |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-11-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-10-13 | 개시 | Berenberg | Buy |
| 2021-09-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-05-25 | 개시 | Craig Hallum | Buy |
| 2020-11-23 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-10-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-02 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-02 | 개시 | Jefferies | Hold |
| 2020-03-02 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
슈뢰딩거 주식(SDGR)의 최신 뉴스
Schrodinger, Inc. Earnings Call: Growth Amid Challenges - TipRanks
Citi Affirms Buy Rating on Schrödinger (SDGR) amid Expanded Collaboration with Ajax Therapeutics - MSN
Schrödinger maintains 10–15% software revenue growth guidance while advancing SGR-1505 clinical program - MSN
Earnings call transcript: Schrodinger beats Q2 2025 forecasts, stock dips - Investing.com
Schrödinger, Inc. Reports Strong Q2 2025 Results - TipRanks
Decoding Schrodinger Inc (SDGR): A Strategic SWOT Insight - GuruFocus
Schrödinger's Dual-Track Strategy: Software Growth and Clinical Pipeline Progress - AInvest
Schrödinger's Q2 2025: Unpacking Contradictions in Customer Engagement, Toxicology Feedback, and Revenue Confidence - AInvest
Schrödinger, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:SDGR) - Seeking Alpha
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Schrödinger (SDGR) Q2 2025 Earnings Transcript - Mitrade
Schrodinger Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Schrödinger Q2 2025 slides: Revenue grows 16% as company maintains full-year guidance By Investing.com - Investing.com South Africa
Schrödinger Q2 2025 slides: Revenue grows 16% as company maintains full-year guidance - Investing.com
Schrodinger earnings beat by $0.15, revenue topped estimates - Investing.com India
Schrodinger Inc (SDGR) Q2 2025 Earnings: EPS of -$0.59 Beats Estimate, Revenue Surpasses Forecast at $54.8 Million - GuruFocus
Schrödinger Reports Second Quarter 2025 Financial Results - Yahoo Finance
Earnings To Watch: Schrodinger Inc (SDGR) Reports Q2 2025 Result - Yahoo Finance
What drives Schrödinger Inc. stock priceInvest smarter with real-time trading alerts - Jammu Links News
What are the technical indicators suggesting about Schrödinger Inc.Get real-time updates on market trends - Jammu Links News
Does Schrödinger Inc. stock perform well during market downturnsBuild a winning investment strategy - Jammu Links News
How volatile is Schrödinger Inc. stock compared to the marketGet exclusive access to expert stock recommendations - Jammu Links News
What catalysts could drive Schrödinger Inc. stock higher in 2025Record-breaking capital gains - Jammu Links News
Is Schrödinger Inc. a good long term investmentTriple-digit growth rates - Jammu Links News
When is Schrödinger Inc. stock expected to show significant growthBreakout profit opportunities - Jammu Links News
Is Opendoor Technologies a Millionaire-Maker Stock? - The Globe and Mail
Will Schrödinger Inc. outperform the marketGrowth Focused Entry Plan Suggestions Issued - metal.it
Live Scanner Shows Breakout on Schrödinger Inc.Low Risk Picks for Daily Trading Released - metal.it
Is Schrödinger's (SDGR) Expanded Ajax Partnership Shaping Its Drug Discovery Revenue Potential? - simplywall.st
Screener Results Flag Schrödinger Inc. as OversoldTarget Return Focused Trade Insights Shared - beatles.ru
Is Schrödinger Inc. stock overvalued or undervaluedUnlock steady growth with low-risk stocks - Jammu Links News
Schrodinger SDGR Q2 2025 Earnings Preview Upside Potential on Strong Software Revenue Growth - AInvest
How many analysts rate Schrödinger Inc. as a “Buy”Unlock daily market insights for better trades - Jammu Links News
Is Schrödinger Inc. a growth stock or a value stockMaximize returns with strategic trading plans - Jammu Links News
What makes Schrödinger Inc. stock price move sharplyTriple Return With Stability - metal.it
Schrödinger to Announce Second Quarter 2025 Financial Results on August 6 - 01net
Schrödinger to Announce Second Quarter 2025 Financial Results on August 6 | SDGR Stock News - GuruFocus
What analysts say about Schrödinger Inc. stockUnmatched market gains - Autocar Professional
Is Schrödinger Inc. stock overhyped or has real potentialExceptional profit velocity - Jammu Links News
Schrödinger Inc. Stock Analysis and ForecastDynamic growth stocks - PrintWeekIndia
Schrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - MSN
슈뢰딩거 (SDGR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
슈뢰딩거 주식 (SDGR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Akinsanya Karen | President of R&D, Therapeutics |
Apr 14 '25 |
Sale |
25.09 |
16,723 |
419,570 |
15,625 |
1.49%
1.37%
자본화:
|
볼륨(24시간):